查詢結果分析
相關文獻
- Blood Lipid Distrbution in Patients with Newly-Diagnosed, Non-Insulin-Dependent Diabetes Mellitus
- Surgical Excision of the Tendon Xanthoma in Familial Hypercholesterolemia--a Case Report
- Comparative Efficacy and Safety of Pravastatin and Fenofibrate on Primary Hypercholesterolemia in a Taiwanese Community
- Lack of Effect of Simvastatin on Insulin Sensitivity in Type 2 Diabetic Patients with Hypercholesterolaemia: Results from a Double-Blind, Randomized, Placebo-Controlled Crossover Study
- Statins類藥物與骨質疏鬆症的關係
- 成人高膽固醇血症之偵測、評估及治療--ATPⅢ摘要
- 從史塔丁的發明談高膽固醇血症的治療
- Short-Term Effects of Simvastatin in Chinese Patients with Primary Hypercholesterolemia
- Efficacy and Safety of Fluvastatin in Patients with Non-Insulin-Dependent Diabetes Mellitus and Hypercholesterolemia
- 高膽固醇血症患者對飲食治療的效果--金山社區三個月的經驗
頁籤選單縮合
題名 | Efficacy and Tolerability of Cerivastatin in Patients with Primary Hypercholesterolaemia=Cerivastatin治療原發性高膽固醇血症之療效及忍受度 |
---|---|
作者 | 謝昌勳; 裴馰; 洪乙仁; 吳令怡; 何志聰; 楊朝欽; 郭熙文; Hsieh, Chang-hsun; Pei, Dee; Hung, Yi-jen; Wu, Ling-yi; He, Chih-tsueng; Yang, Tsao-chin; Kuo, Shi-wen; |
期刊 | Journal of Medical Sciences |
出版日期 | 20021200 |
卷期 | 22:6 2002.12[民91.12] |
頁次 | 頁277-282 |
分類號 | 418.227 |
語文 | eng |
關鍵詞 | 高膽固醇血症; Cerivastatin; HMG-CoA reductase inhibitors; Hypercholesterolaemia; |
英文摘要 | Background: Cerivastatin is a new member of a class of lipid-lowering agents shown to be beneficial to both primary and secondary prevention of coronary events and mortality in hyperlipidemic patients. The purpose of our study is to assess the efficacy and tolerability of cerivastatin (0.2 mg once daily) in patients with primary hypercholesterolaemia. Patients and methods: A single-blind study was designed. Sixteen patients (5 male, 11 female) with primary hypercholesterolaemia, defined as fasting low-density lipoprotein-cholesterol (LDL C) > 160 mg/dL and triglyceride (TG) level < 160 mg/dL were recruited. All patients received 2 months of diet control, followed by a 2 months of diet control plus placebo, and finally 2 months of diet control plus cerivastatin (0.2 mg daily taken at bedtime). Results: Cerivastatin significantly reduced serum levels of total cholesterol (TC) compared with levels after diet alone or diet plus placebo ( 16.11% vs. –2.00% or +1.90%, p< 0.01), LDL-C compared with levels after diet alone or diet plus placebo ( 20.07% vs. –0.70% or +5.0%, p< 0.01), and TG compared with levels after diet alone or diet plus placebo (–15.19% vs. +7.70% or +0.48%, p< 0.05). The increase in high density lipoprotein-cholesterol (HDL C) levels was significant when compared with levels after diet alone or diet plus placebo (+13.35% vs. –0.10% or +3.20%, p<0.01 or p< 0.05, respectively). All patients completed this study. No deaths or serious adverse events occurred. Conclusion: Cerivastatin 0.2 mg once daily for 2 months was effective in our clinical trials in significantly reducing serum TC, LDL-C, TG and increasing serum HDL-C levels in patients with primary hypercholesterolaemia. When not combined with fibrates, cerivastatin could be administered safely to these patients. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。